Completing data — refresh the page later to see the latest
224624-80-0O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)OHZLAWYIBLZNRFZ-VXGBXAGGSA-NMiridesap has been used in trials studying the prevention of HIV and treatment of AL amyloidosis.
224624-80-0DTXSID00176996CHEMBL25263Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P264+P265, P270, P280, P301+P317, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P330, P363, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
DescriptionSerum amyloid P (SAP) is pentraxin with roles in inflammation and immune response. CPHPC is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance. It also produces significant reduction of SAP from cerebrospinal fluid and visceral amyloid deposits. CPHPC has been used with anti-SAP antibodies to eliminate amyloid deposits in clinical trials of systemic amyloidosis.
UsesMiridesap is a potential drug in the treatment of amyloidosis.